Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. BUZZ, LLC
WARNING LETTER
•BUZZ, LLC

FDA WARNING_LETTER - BUZZ, LLC

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore BUZZ, LLC
Record Details

The FDA issued a Warning Letter to cheap-phentermine-online.net after reviewing its website and determining that the firm is illegally offering products for sale in violation of the Federal Food, Drug, and Cosmetic Act. Products such as "Acomplia," "Rimonabant," "Herbal Ambien," "Herbal Xanax," "Viagra," "Phentermine," "Xanax," "Valium," and "Ambien" are considered drugs under Section 201(g) of the Act. The firm is marketing unapproved new drugs, including "Acomplia (Brand/Generic)," "Rimonabant," "Herbal Ambien," and "Herbal Xanax," which are defined as "new drugs" under Section 201(p). Their sale without FDA-approved applications violates Sections 301(d) and 505(a). Rimonabant was specifically rejected by FDA due to severe neurological and psychiatric side effects. Additionally, the firm sells misbranded drugs like "Viagra," "Phentermine," "Xanax," "Valium," and "Ambien" without requiring a prescription, violating Section 503(b)(1) and Sections 301(a), 301(b), and 301(k). The website also falsely claims products are FDA-approved and misleads consumers by suggesting "Herbal Ambien" and "Herbal Xanax" contain active ingredients of approved drugs, making them misbranded under Section 502(a). The introduction of these misbranded products into interstate commerce violates Section 301(a). The FDA requires the firm to immediately cease marketing violative products and respond within 15 working days, detailing corrective actions to prevent recurrence. Failure to comply may result in regulatory actions like seizure or injunction.

Company
BUZZ, LLC
Product Type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Deborah M. Autor (Former FDA Deputy Commissioner)
Open in Dashboard

ID · bf4b6a2c-ce55-4a1b-9055-36239edf94d3

Violation Codes9
21 U.S.C. 353(b)(1)21 U.S.C. 321(g)21 U.S.C. 321(p)21 U.S.C. 331(d)21.U.S.C. 355(a)21 U.S.C. 331(b)21 U.S.C. 331(k)21 U.S.C. 352(a)21 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

KeyPedia
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.